Details of the Drug Formulations
General Information of Drug (ID: DMA5XGH)
Drug Name | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
|
|||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||
Therapeutic Class |
Antihypertensive Agents
|
|||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||
Full List of Drug Formulations Containing This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488). | ||||
---|---|---|---|---|---|
2 | ClinicalTrials.gov (NCT00367211) Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.. U.S. National Institutes of Health. | ||||